“Today, we released an analysis on COVID-19 mRNA vaccines that the public needs to be aware of. This analysis showed an increased risk of cardiovascular death in men 18–39. FL will not remain silent on the truth, Ladapo tweeted.
mRNA Covid19 mortality after vaccination studied
The Florida Department of Health conducted an analysis through self-controlled case series, a technique originally developed to evaluate vaccine safety. It studied the risk of mortality after mRNA COVID-19 vaccination.
The analysis found an 84 percent increase in the relative incidence of cardiovascular death among men ages 18-39 within 28 days following mRNA vaccination, read an advisory from Florida Health signed by Florida Governor Ron DeSantis and Ladapo.
It further advised individuals with pre-existing heart conditions, such as myocarditis and pericarditis, to take special precautions when considering vaccination and to discuss this with their healthcare provider.
With high levels of global immunity to COVID-19, the unusually high risk of cardiovascular death in men in this age group is likely to benefit vaccination. These increased risks were not found in non-mRNA vaccines, read a Florida Department of Health bulletin.
“The study of the safety and efficacy of any drug, including vaccines, is an important component of public health,” said Surgeon General Dr. Joseph Ladapo.
“There has been little attention to safety and concerns of many individuals have been dismissed – these are important findings that should be communicated to Floridians,” Ladapo said.
India will soon get its first mRNA vaccine
Meanwhile, India’s first mRNA Covid-19 vaccine is likely to be available soon. The Drug Controller General of India (DCGI) is expected to grant emergency use authorization for Genova’s mRNA vaccine soon.
The company has conducted Phase 2 and Phase 3 data trials on 4000 participants to evaluate vaccine safety, immunogenicity and tolerability.
The vaccine – GEMCOVAC-19 – is the country’s first indigenous mRNA Covid-19 vaccine.
According to Genoa officials, trial data showed that the vaccine was safe and well-tolerated. Immunogenicity measured 2 weeks after dosing showed that GEMCOVAC-19 is non-inferior to CoVShield.
The two-dose vaccine must be administered intramuscularly at 28-day intervals.
As the COVID-19 pandemic spread, an mRNA vaccine candidate was the first to enter human trials globally. The first two vaccines that were made available for use in the US were based on mRNA technology.
How do mRNA vaccines work?
Unlike vaccines that insert a weakened or inactivated virus into your body to activate an immune response, these two COVID-19 vaccines (Pfizer-BioNtech and Moderna) use messenger RNA, or mRNA, to deliver messages to your immune system.
Basically, the technology uses genetically engineered mRNA to instruct cells to make the S-protein found on the surface of the COVID-19 virus. According to the US-based Mayo Clinic report, after vaccination, muscle cells begin to make fragments of the S-protein and begin to display them on cell surfaces. This leads to the formation of antibodies in the body.